Abstract:Abstract Background: ERBB2 (HER2) insertions and point mutations are oncogenic drivers in non-small cell lung cancer (NSCLC) and now has approved targeted therapy for this patient population. Here, we present the landscape of ERBB2 genetic alterations (alts) and co-mutations, and the comparison between ERBB2 and EGFR exon 20 insertions in NSCLC. Methods: Two large retrospective cohorts were analyzed. In the Geneplus (China) cohort, 1,281 newly diagnosed NSCLC patients (pts) harboring ERBB2 alt were analyzed based on tissue and/or ctDNA. In the Guardant360 (Guardant Health, Redwood City, USA) cohort, 1719 ctDNA profiles of newly diagnosed NSCLC samples harboring ERBB2 alts were evaluated, with clonal alterations defined as those with ≥50% ratio of the maximum somatic variant allele fraction. Results: In the Geneplus cohort of 1,281 pts with ERBB2 alts, 55% were female with a median age of 58 years. ERBB2 mutations or insertions were identified in 930 pts, ERBB2 amplification(amp)-only in 351 pts, with mutation and co-amp at 7.5%. Most common alterations were in the tyrosine kinase domain exon 20 (85%), with Y772_A775dupYVMA to be the most frequent (57.4%), followed by G776delinsVC/LC/VV/IC (10.6%), and S310X (10.4%). EBRR2-mutation NSCLC were frequently having PDL1<1% (63%) and low TMB (mean 3.5). TP53 and EGFR were most frequent co-mutations. CDK12 amp was frequently co-occurring with ERBB2 amp as both were located to Chr17q12. In the Guardant360 cohort, 54% were female with a median age of 70 years. 634 had COSMIC/OncoKB annotated oncogenic mutations. Similar to Geneplus, Y772_A775dupYVMA (39.4%), S310F (10.7%), G776delinsVC/LC/VV (9.7%) were the most common alterations. Using Y772/G776/G778 insertion as the control, a clonality cut-off of 50% had a positive prediction value of 87.5%. When this clonality cut-off was applied to all the other variants of unknown significance (VUS), 335 (19%) samples had clonal mutations with S335 (n=9), D277Y (n=6), R499W (n=4), and G222C (n=4) being most frequent. Comparison between ERBB2 Exon20 (n=370) to EGFR (ERBB1) exon20 insertions (n=323) showed a different distribution of patterns with greater heterogeneity in EGFR exon20 insertions. Conclusion: In two large independent cohorts, Chinese and Western, ERBB2 mutation and co-mutation patterns were similar. ERBB2 exon 20 insertions/mutations were dominant at over 80% with Y772_A775dupYVMA being the most common driver mutation; TP53 and EGFR were the most frequently co-occurred genes. ERBB2 mutation lung cancers had low TMB and PDL1, as expected in female dominant lung adenocarcinomas, similar to EGFR exon 20 NSCLC. Clonal VUSs may represent a novel subset of mutations to functionally characterize. Citation Format: Lingzhi Hong, Leylah Drusbosky, Yinyi Wang, Yuanyuan Xiong, Rongrong Chen, Simon Heeke, Monique B. Nilsson, Jianjun Zhang, John V. Heymach, Xiuning Le. Mutation and co-mutation landscape ofERBB2 alterations in advanced NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6087.

ERBB2 Mutation: A Promising Target in Non-Squamous Cervical Cancer

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Mutational Analysis Ofkrasand Its Clinical Implications in Cervical Cancer Patients

ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma

ERBB3 Mutations in Advanced Gastric Signet-Ring Cell Carcinoma (SRCC) and the Implications for Targeted Therapy

Efficacy of immune checkpoint inhibitors in patients with non–small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype

Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations

Abstract PO2-08-05: ERBB2 mutated breast cancer detected by next generation sequencing: integrated analysis based on real-world data and The Cancer Genome Atlas

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

IDDF2020-ABS-0177 ERBB4 High Expression and Mutations in Gastric Cancer Present Opportunities for Clinical Landscape and Therapeutic Development

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

Molecular and Clinicopathological Characteristics of ERBB2 Gene Fusions in 32,131 Chinese Patients with Solid Tumors.

Abstract 6087: Mutation and Co-Mutation Landscape Oferbb2 Alterations in Advanced NSCLC

Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers

Abstract 5536: Landscape and Analysis of ERBB2 Amplification and Short Variant Mutations in Large-Scale Chinese Patients with Colorectal Cancer

Abstract 4333: High Incidence of ERBB2 Amplification Associated with Microsatellite Stable Status in Chinese Colorectal Cancer Patients

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions

Association of ERCC Family Mutations with Prognosis and Immune Checkpoint Inhibitors Response in Multiple Cancers